These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 7834215)

  • 1. Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors.
    Boyer JL; Zohn IE; Jacobson KA; Harden TK
    Br J Pharmacol; 1994 Oct; 113(2):614-20. PubMed ID: 7834215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 264.7 macrophages.
    Chen BC; Lee CM; Lin WW
    Br J Pharmacol; 1996 Dec; 119(8):1628-34. PubMed ID: 8982511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of antagonists to characterize the receptors mediating depolarization of the rat isolated vagus nerve by alpha, beta-methylene adenosine 5'-triphosphate.
    Trezise DJ; Kennedy I; Humphrey PP
    Br J Pharmacol; 1994 May; 112(1):282-8. PubMed ID: 8032652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The P2Y purinoceptor in rat brain microvascular endothelial cells couple to inhibition of adenylate cyclase.
    Webb TE; Feolde E; Vigne P; Neary JT; Runberg A; Frelin C; Barnard EA
    Br J Pharmacol; 1996 Dec; 119(7):1385-92. PubMed ID: 8968547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of P2-purinoceptor antagonists at two relaxation-mediating P2-purinoceptors in guinea-pig taenia coli.
    Bültmann R; Dudeck O; Starke K
    Naunyn Schmiedebergs Arch Pharmacol; 1996 Mar; 353(4):445-51. PubMed ID: 8935712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent agonist action of 2-thioether derivatives of adenine nucleotides at adenylyl cyclase-linked P2Y-purinoceptors.
    Boyer JL; O'Tuel JW; Fischer B; Jacobson KA; Harden TK
    Br J Pharmacol; 1995 Nov; 116(6):2611-6. PubMed ID: 8590978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPADS and suramin as antagonists at cloned P2Y- and P2U-purinoceptors.
    Charlton SJ; Brown CA; Weisman GA; Turner JT; Erb L; Boarder MR
    Br J Pharmacol; 1996 Jun; 118(3):704-10. PubMed ID: 8762097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADP-evoked phospholipase C stimulation and adenylyl cyclase inhibition in glioma C6 cells occur through two distinct nucleotide receptors, P2Y(1) and P2Y(12).
    Czajkowski R; Lei L; Sabała P; Barańska J
    FEBS Lett; 2002 Feb; 513(2-3):179-83. PubMed ID: 11904146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-existence of P2Y-and PPADS-insensitive P2U-purinoceptors in endothelial cells from adrenal medulla.
    Mateo J; Miras-Portugal MT; Castro E
    Br J Pharmacol; 1996 Nov; 119(6):1223-32. PubMed ID: 8937727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel P2-purinoceptor expressed by a subpopulation of astrocytes from the dorsal spinal cord of the rat.
    Ho C; Hicks J; Salter MW
    Br J Pharmacol; 1995 Dec; 116(7):2909-18. PubMed ID: 8680724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fidelity in functional coupling of the rat P2Y1 receptor to phospholipase C.
    Schachter JB; Boyer JL; Li Q; Nicholas RA; Harden TK
    Br J Pharmacol; 1997 Nov; 122(6):1021-4. PubMed ID: 9401764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and pharmacology of selective P2-purinoceptor antagonists.
    Lambrecht G
    J Auton Pharmacol; 1996 Dec; 16(6):341-4. PubMed ID: 9131412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second messenger cascade specificity and pharmacological selectivity of the human P2Y1-purinoceptor.
    Schachter JB; Li Q; Boyer JL; Nicholas RA; Harden TK
    Br J Pharmacol; 1996 May; 118(1):167-73. PubMed ID: 8733591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPADS: an antagonist at endothelial P2Y-purinoceptors but not P2U-purinoceptors.
    Brown C; Tanna B; Boarder MR
    Br J Pharmacol; 1995 Nov; 116(5):2413-6. PubMed ID: 8581277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of competitive antagonists of the P2Y1 receptor.
    Boyer JL; Romero-Avila T; Schachter JB; Harden TK
    Mol Pharmacol; 1996 Nov; 50(5):1323-9. PubMed ID: 8913364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional characterisation of P2 purinoceptors in PC12 cells by measurement of radiolabelled calcium influx.
    Michel AD; Grahames CB; Humphrey PP
    Naunyn Schmiedebergs Arch Pharmacol; 1996 Nov; 354(5):562-71. PubMed ID: 8938653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrimination by PPADS between endothelial P2Y- and P2U-purinoceptors in the rat isolated mesenteric arterial bed.
    Ralevic V; Burnstock G
    Br J Pharmacol; 1996 May; 118(2):428-34. PubMed ID: 8735648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrimination between two types of P2 purinoceptors by suramin in rat hepatocytes.
    Tomura H; Okajima F; Kondo Y
    Eur J Pharmacol; 1992 Aug; 226(4):363-5. PubMed ID: 1397062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P2-purinoceptors mediating spasm of the isolated uterus of the non-pregnant guinea-pig.
    Piper AS; Hollingsworth M
    Br J Pharmacol; 1996 Apr; 117(8):1721-9. PubMed ID: 8732282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A molecularly identified P2Y receptor simultaneously activates phospholipase C and inhibits adenylyl cyclase and is nonselectively activated by all nucleoside triphosphates.
    Boyer JL; Delaney SM; Villanueva D; Harden TK
    Mol Pharmacol; 2000 Apr; 57(4):805-10. PubMed ID: 10727529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.